Tarsus Pharmaceuticals Common Stock Shares Outstanding Over Time
| TARS Stock | USD 46.58 0.31 0.66% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Tarsus Pharmaceuticals Performance and Tarsus Pharmaceuticals Correlation. Tarsus |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tarsus Pharmaceuticals. If investors know Tarsus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tarsus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.75) | Revenue Per Share 3.571 | Quarterly Revenue Growth 24.718 | Return On Assets (0.27) | Return On Equity (0.60) |
The market value of Tarsus Pharmaceuticals is measured differently than its book value, which is the value of Tarsus that is recorded on the company's balance sheet. Investors also form their own opinion of Tarsus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Tarsus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tarsus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Tarsus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tarsus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tarsus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tarsus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Common Stock Shares Outstanding Analysis
Compare Tarsus Pharmaceuticals and related stocks such as LianBio ADR, Aldeyra, and Travere Therapeutics Common Stock Shares Outstanding Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALDX | 4.8 M | 4.8 M | 4.5 M | 4.8 M | 3.9 M | 8.6 M | 11.4 M | 15.9 M | 21.7 M | 27.1 M | 34 M | 54 M | 58.4 M | 58.9 M | 61.9 M |
| TVTX | 95.9 M | 106.7 K | 3.7 M | 14.2 M | 25.1 M | 37.6 M | 38.3 M | 38.8 M | 40.4 M | 42.3 M | 47.5 M | 59.8 M | 63.8 M | 74.3 M | 45.7 M |
| ETON | 16.3 M | 16.3 M | 16.3 M | 16.3 M | 16.3 M | 16.3 M | 16.3 M | 16.3 M | 6.4 M | 17.8 M | 21 M | 25.2 M | 25.1 M | 25.6 M | 21.6 M |
| CNTB | 55.8 M | 55.8 M | 55.8 M | 55.8 M | 55.8 M | 55.8 M | 55.8 M | 55.8 M | 55.8 M | 55.8 M | 53.9 M | 52.3 M | 55 M | 55.1 M | 43.5 M |
| ABOS | 40.2 M | 40.2 M | 40.2 M | 40.2 M | 40.2 M | 40.2 M | 40.2 M | 40.2 M | 40.2 M | 40.2 M | 40.2 M | 40.5 M | 40.6 M | 48.6 M | 46.2 M |
| NUVB | 206.7 M | 206.7 M | 206.7 M | 206.7 M | 206.7 M | 206.7 M | 206.7 M | 206.7 M | 206.7 M | 206.7 M | 97.5 M | 197.9 M | 216.7 M | 218.9 M | 206.3 M |
| ELDN | 94.8 K | 94.8 K | 94.8 K | 94.8 K | 39.9 K | 138.8 K | 21.3 K | 259.9 K | 500.3 K | 655.5 K | 1.5 M | 14.8 M | 14.3 M | 24.6 M | 25.9 M |
| OPT | 2.8 M | 6 M | 6.2 M | 6.2 M | 13.6 M | 18.8 M | 20.2 M | 25.2 M | 30.9 M | 34.6 M | 42.5 M | 46.6 M | 58.7 M | 638.2 M | 670.1 M |
| CNTA | 70.9 M | 70.9 M | 70.9 M | 70.9 M | 70.9 M | 70.9 M | 70.9 M | 70.9 M | 70.9 M | 70.9 M | 142.1 M | 90 M | 93.4 M | 96.2 M | 108.4 M |
| NUVL | 48.3 M | 48.3 M | 48.3 M | 48.3 M | 48.3 M | 48.3 M | 48.3 M | 48.3 M | 48.3 M | 48.3 M | 48.3 M | 48.3 M | 49.7 M | 58.2 M | 55.6 M |
| GNFT | 11.6 M | 12.9 M | 15.3 M | 20 M | 23 M | 24.7 M | 26.9 M | 31.2 M | 31.2 M | 37 M | 38.9 M | 55.6 M | 49.7 M | 49.7 M | 28.1 M |
| GLUE | 44 M | 44 M | 44 M | 44 M | 44 M | 44 M | 44 M | 44 M | 44 M | 44 M | 44 M | 46.5 M | 47.2 M | 51.4 M | 51.3 M |
| DSGN | 27.2 M | 27.2 M | 27.2 M | 27.2 M | 27.2 M | 27.2 M | 27.2 M | 27.2 M | 27.2 M | 27.2 M | 27.2 M | 45.9 M | 55.7 M | 56 M | 46.6 M |
| HOWL | 28.7 M | 28.7 M | 28.7 M | 28.7 M | 28.7 M | 28.7 M | 28.7 M | 28.7 M | 28.7 M | 28.7 M | 28.7 M | 27.3 M | 28.9 M | 35.6 M | 32.8 M |
| IKNA | 35.9 M | 35.9 M | 35.9 M | 35.9 M | 35.9 M | 35.9 M | 35.9 M | 35.9 M | 35.9 M | 35.9 M | 35.9 M | 36 M | 36.2 M | 41.7 M | 40.8 M |
| STOK | 12.8 M | 12.8 M | 12.8 M | 12.8 M | 12.8 M | 12.8 M | 12.8 M | 12.8 M | 23.5 M | 18 M | 33.5 M | 36.7 M | 38.9 M | 44 M | 32.6 M |
| PEPG | 22.4 M | 22.4 M | 22.4 M | 22.4 M | 22.4 M | 22.4 M | 22.4 M | 22.4 M | 22.4 M | 22.4 M | 22.4 M | 22.4 M | 23.7 M | 23.8 M | 25.2 M |
| TYRA | 42.5 M | 42.5 M | 42.5 M | 42.5 M | 42.5 M | 42.5 M | 42.5 M | 42.5 M | 42.5 M | 42.5 M | 42.5 M | 41.4 M | 41.9 M | 42.7 M | 33.8 M |
| TRDA | 31.2 M | 31.2 M | 31.2 M | 31.2 M | 31.2 M | 31.2 M | 31.2 M | 31.2 M | 31.2 M | 31.2 M | 31.2 M | 31.2 M | 31.3 M | 33.1 M | 34.8 M |
| PHVS | 30.5 M | 30.5 M | 30.5 M | 30.5 M | 30.5 M | 30.5 M | 30.5 M | 30.5 M | 31.8 M | 4.8 M | 30.5 M | 30.4 M | 33.6 M | 38.4 M | 31.4 M |
| RLYB | 32.1 M | 32.1 M | 32.1 M | 32.1 M | 32.1 M | 32.1 M | 32.1 M | 32.1 M | 32.1 M | 32.1 M | 32.1 M | 32.1 M | 31.8 M | 40.4 M | 37.1 M |
Tarsus Pharmaceuticals and related stocks such as LianBio ADR, Aldeyra, and Travere Therapeutics Common Stock Shares Outstanding description
The total number of shares of a company's common stock that are currently owned by all its shareholders.My Equities
My Current Equities and Potential Positions
| Tarsus Pharmaceuticals | TARS |
| Classification | Biotech |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 46.58
Additional Tools for Tarsus Stock Analysis
When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.